Cargando…

Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study

OBJECTIVE: To evaluate the safety and efficacy of hCDR1 (Edratide) in patients with systemic lupus erythematosus (SLE). METHODS: Patients (n=340) with SLE ≥4 ACR criteria (4–11, mean 7) with active disease (SLEDAI-2K of 6–12). Patients were on average 7.1 years post-diagnosis and their organ involve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Urowitz, Murray B, Isenberg, David A, Wallace, Daniel J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Clinical Trials and Drug Discovery
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538379/ https://www.ncbi.nlm.nih.gov/pubmed/26301100 http://dx.doi.org/10.1136/lupus-2015-000104

Ejemplares similares

The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness
por: Gracia-Tello, Borja, et al.
Publicado: (2017)

Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study
por: Jin, Hui-Zhi, et al.
Publicado: (2023)

The Tolerogenic Peptide, hCDR1, Down-Regulates the Expression of Interferon-α in Murine and Human Systemic Lupus Erythematosus
por: Sthoeger, Zev, et al.
Publicado: (2013)

Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways
por: Dörner, Thomas, et al.
Publicado: (2020)

Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials
por: Kim, Mimi, et al.
Publicado: (2018)

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
por: Merrill, Joan T, et al.
Publicado: (2018)

Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort
por: Yap, K S, et al.
Publicado: (2015)

Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
por: Riggs, Jeffrey M, et al.
Publicado: (2018)

Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study
por: van Vollenhoven, Ronald F, et al.
Publicado: (2018)

Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study
por: Jiang, Nan, et al.
Publicado: (2022)

Peripheral neuropathy in systemic lupus erythematosus: what can neuromuscular ultrasonography (NMUS) tell us? A cross-sectional study
por: Mahran, Safaa A, et al.
Publicado: (2021)

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
por: Tummala, Raj, et al.
Publicado: (2021)

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA
por: Collins, C E, et al.
Publicado: (2016)

Utility of the ACR-1997, SLICC-2012 and EULAR/ACR-2019 classification criteria for systemic lupus erythematosus: a single-centre retrospective study
por: Lu, Wentian, et al.
Publicado: (2022)

Standard medical care of patients with systemic lupus erythematosus (SLE) in large specialised centres: data from the Russian Federation, Ukraine and Republic of Kazakhstan (ESSENCE)
por: Nasonov, E, et al.
Publicado: (2015)

Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus
por: Sullivan, B A, et al.
Publicado: (2016)

Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE
por: Kamen, Diane L, et al.
Publicado: (2022)

Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)
por: Dyball, Sarah, et al.
Publicado: (2021)

Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers
por: Arriens, Cristina, et al.
Publicado: (2020)

Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
por: Tummala, Raj, et al.
Publicado: (2018)

Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study
por: Furie, Richard, et al.
Publicado: (2016)

Anifrolumab for systemic lupus erythematosus
Publicado: (2022)

Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis
por: Tian, Jingru, et al.
Publicado: (2018)

Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study
por: Furie, Richard A, et al.
Publicado: (2017)

First use of cenerimod, a selective S1P(1) receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study
por: Hermann, Viktoria, et al.
Publicado: (2019)

SLE clinical trials: impact of missing data on estimating treatment effects
por: Kim, Mimi, et al.
Publicado: (2019)

Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies
por: Tselios, Konstantinos, et al.
Publicado: (2016)

Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus
por: Tselios, Konstantinos, et al.
Publicado: (2021)

Repeated Evolution of Inactive Pseudonucleases in a Fungal Branch of the Dis3/RNase II Family of Nucleases
por: Ballou, Elizabeth R, et al.
Publicado: (2020)

Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents
por: Lougheed, Kathryn E.A., et al.
Publicado: (2011)

Serial image analysis of Mycobacterium tuberculosis colony growth reveals a persistent subpopulation in sputum during treatment of pulmonary TB
por: Barr, David A., et al.
Publicado: (2016)

Detection and characterization of drug-resistant conferring genes in Mycobacterium tuberculosis complex strains: A prospective study in two distant regions of Ghana
por: Otchere, I.D., et al.
Publicado: (2016)

Baicalein inhibits non‐small‐cell lung cancer invasion and metastasis by reducing ezrin tension in inflammation microenvironment
por: Zhang, Xiaolong, et al.
Publicado: (2020)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Effect of murine double‐minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys
por: Kawata, Yoshiko, et al.
Publicado: (2020)

Intracellular levels of reactive oxygen species correlate with ABT‐263 sensitivity in non‐small‐cell lung cancer cells
por: Ohgino, Keiko, et al.
Publicado: (2020)

Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine
por: Komoto, Kana, et al.
Publicado: (2020)

dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA‐repair‐defective human cancer cells
por: Yokogawa, Tatsushi, et al.
Publicado: (2020)

Extracting Atomic Contributions to Binding Free Energy using Molecular Dynamics Simulations with Mixed Solvents (MDmix)
por: Alvarez-Garcia, Daniel, et al.
Publicado: (2022)

Event Monitoring and Evaluation by Community Pharmacists in Japan: A Pilot Study on Fenofibrate and Pemafibrate
por: Takahashi, Masao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s8am9o8akocrp1k1ij96g4k2d9